Fulcrum Therapeutics (FULC) PT Lowered to $14 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
BofA Securities Reiterates Underperform Rating on Fulcrum Therapeutics (FULC)
May 14, 2024 8:47 AM EDTBofA Securities analyst Tazeen Ahmad reiterated an Underperform rating and $5.00 price target on Fulcrum Therapeutics (NASDAQ: FULC).
The analyst comments "FULC announced the company has entered an exclusive license agreement with Sanofi (ticker: SNY; covered by Graham Perry) for the ex-US development of losmapimod in... More
